HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Factors with remission of fatty liver in patients With type 2 diabetes treated with ipragliflozin

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1507/endocrj.EJ19-0136


Title: Factors with remission of fatty liver in patients With type 2 diabetes treated with ipragliflozin
Authors: Yamauchi, Yuki Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Takahashi, Kiyohiko Browse this author
Takase, Takahiro Browse this author
Yamamoto, Chiho Browse this author
Yokota, Isao Browse this author →KAKEN DB
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: Fatty liver
Ipragliflozin
Diabetes
Issue Date: 2019
Publisher: The Japan Endocrine Society
Journal Title: Endocrine journal
Volume: 66
Issue: 11
Start Page: 995
End Page: 1000
Publisher DOI: 10.1507/endocrj.EJ19-0136
Abstract: We investigated the factors associated with fatty liver remission via treatment with ipraglitlozin. The analysis was obtained from our multi-center prospective observational study, including 200 Japanese patients with type 2 diabetes treated with ipragliflozin (50 mg/day) for 24 weeks. The extent of fatty liver was estimated using a fatty liver index (FLI). Based on the FLI after the treatment with ipragliflozin, patients were classified into remission group (FLI < 30) and non-remission group (FLI >= 30). After treatment with ipragliflozin for 24 weeks, FLI significantly improved from 64.5 +/- 21.6 to 51.9 +/- 26.5 (p < 0.01). Body weight, body mass index, waist circumference, aspartate aminotransferase, alanine aminotransferase, and FLI in the remission group were significantly lower compared with those of the non-remission group. Stepwise analysis showed that the baseline FLI (Odds ratio 0.86; 95% confidence interval 0.81-0.90, p < 0.01) was an independent factor associated with FLI remission. Using a receiver operating characteristic (ROC) analysis, the adequate cut-off value for the remission was 50. The area under the ROC curve was 0.93 with the sensitivity and specificity 84.6% and 90.1% respectively. In conclusion, ipragliflozin ameliorated fatty liver. These results suggest that patients with fatty liver with a lower FLI are more likely to attain remission by the treatment with ipraglitlozin.
Type: article
URI: http://hdl.handle.net/2115/76513
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University